Biohaven Ltd. (BHVN) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.04: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 3.11; Below-average business quality.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and... Read more
Sell if holding. Engine safety override at $11.04: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 3.11; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 65. Score 4.9/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 62d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Biohaven Ltd.
Latest news
- NEWS Biohaven Initiates First-In-Human Dosing For BHV-8100 Pyruvate Kinase M2 Isoform Modulator — benzinga Jun 1, 2026 positive
- NEWS Biohaven Presents New Patient Data From Its BHV-1300 MoDE Degrader For Graves' Disease, BHV-1400 Trap Degrader For IgA N — benzinga May 27, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target — benzinga May 26, 2026 neutral
- NEWS Biohaven Presents New Data From Kv7.2/7.3 Channel Activator Program To Treat Focal Epilepsy — benzinga May 26, 2026 positive
- NEWS Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $18 — benzinga May 13, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 9.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.04: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 3.11; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 65. Prior stop was $10.23. Score 4.9/10, moderate confidence.
Take-profit target: $19.54 (+77.6% upside). Prior stop was $10.23. Stop-loss: $10.23.
Quality below floor (1.4 < 4.0).
Biohaven Ltd. trades at a P/E of N/A (forward -5.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
25 analysts cover BHVN with a consensus score of 4.0/5. Average price target: $22.
What does Biohaven Ltd. do?Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments...
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.